Huawei dévoile ses produits phares de nouvelle génération lors de l'événement mondial de lancement de produits innovants « Chase the Wild » (« À la recherche de l'authenticité »), organisé à Munich

Huawei a dévoilé sa nouvelle gamme lors de l’événement mondial « Chase the Wild » à Munich, avec notamment la montre connectée HUAWEI Watch GT 7 (46 mm/41 mm) et une offre dédiée aux sports outdoor, ski et cyclisme, ainsi que des fonctions santé améliorées via « Health Insights ». Après une pause d’un an, la Watch 6 revient en Europe et Huawei a aussi lancé la Watch D3 avec tensiomètre certifié CE (mesure avant/après effort). Côté productivité, la tablette HUAWEI MatePad Pro 12" (4,7 mm, 454 g) intègre des fonctionnalités IA de saisie et suivi, tandis que les écouteurs FreeBuds Neo et la série smartphone nova 16s complètent la gamme.

Analysis

This is more important as a signal on category re-bundling than as a single-product event. Huawei is trying to convert wearables from a hardware refresh cycle into a health-and-fitness workflow, which is the right play if the goal is to defend pricing and reduce churn; that puts the most direct pressure on Garmin (GRMN) in outdoor/sports and on mid-tier Android watch vendors, while Apple’s ecosystem lock-in still makes AAPL harder to dislodge.

The more interesting second-order effect is margin compression across the broader accessory stack. If premium watches, tablets, and earbuds increasingly ship with AI coaching, health features, and bundled sensors, the market may start valuing standalone hardware differentiation less and software/service attachment more; that tends to favor ecosystem leaders and punish feature-only brands. In Europe, the CE medical-device angle matters because it lowers adoption friction for health-monitoring use cases, but the monetization remains unproven until there is evidence of repeat usage or payer/doctor relevance.

For tablets and audio, the competitive threat is mostly to Samsung/Lenovo and regional Android OEMs, not to AAPL outright. The big constraint on Huawei is still software availability and channel trust outside China, so the near-term share gain could be real in unit terms but smaller in revenue terms if it relies on discounting. The stock-market read-through is therefore modest: a watch item for premium consumer hardware, not a broad thematic reset.

The contrarian view is that consensus may overestimate Huawei’s ability to translate product breadth into durable share in Europe. Hardware launch cadence is not the bottleneck; distribution, app ecosystem, and geopolitics are. If sell-through data doesn’t validate the launch within one to two quarters, the competitive pressure likely fades back into incremental noise rather than a structural threat.

Key Decisions for Investors

• No immediate directional trade from this release alone; treat it as a channel-check alert on European wearables and tablets over the next 1-2 quarters.
• Watch GRMN closely for any Q4 European sell-through or margin commentary deterioration; if channel checks show share loss, consider a tactical short GRMN versus long AAPL pair with a 3-6 month horizon.
• If Huawei’s health-monitoring features gain traction, expect mid-tier Android watch vendors and regional OEMs to take the first hit; use that as a relative-value signal rather than a broad tech short.
• Set an alert on AAPL and GRMN around upcoming earnings: thesis is falsified if either company shows no Europe share or ASP pressure despite Huawei’s expanded portfolio.